Purpose Although programmed death (PD)-1 pathway inhibitors are now used in nearly all
patients with advanced non–small-cell lung cancer (NSCLC), the large number of patients …

Objectives Although dramatic responses to MET inhibitors have been reported in patients with
MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC), the impact of these …

BACKGROUND Programmed cell death protein 1 inhibitors increasingly are being used to
treat patients with advanced lung carcinomas. Programmed death‐ligand 1 (PD‐L1) …

Background Clinically-available biomarkers to identify the fraction of patients with small cell
lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High …

Age-related macular degeneration (AMD) is a leading cause of severe vision loss. With our
aging population, it may affect 288 million people globally by the year 2040. AMD progresses …

Purpose The purpose of this study was to evaluate Computer Vision Syndrome (CVS) in
undergraduate and medical students since transitioning to online learning during the COVID-19 …

8511 Background: Dramatic responses to MET inhibitors have been reported in patients with
NSCLC harboring activating mutations that cause MET exon 14 (METdel14) skipping. We …

Purpose The application of artificial intelligence (AI) in diagnosing and managing ocular
disease has gained popularity as research highlights the utilization of AI to improve …

Mohs micrographic surgery (MMS) is considered the gold standard for treating high-risk
cutaneous basal cell carcinoma (BCC), but is expensive, time-consuming, and can be …

Purpose: We pursued genomic analysis of an exceptional responder with non–small cell
lung cancer (NSCLC) through a multi-platform effort to discover novel oncogenic targets. …